Preserving the cognitive trajectory
The cognitive trajectory after age 50 depends on four measurable foundations: deep sleep, muscular strength, B vitamins and mitochondrial function. This section indexes the documented levers and accessible markers; detailed protocols are in the corresponding sections.
The foundations that decide
No single bioactive compensates for chronically irregular sleep, declining strength or elevated homocysteine. The levers below act in convergence on the cognitive trajectory.
Deep sleep and the glymphatic system
Slow-wave sleep activates the cerebral glymphatic system, the evacuation pathway for metabolites between cerebrospinal fluid and the interstitial compartment. The cerebral interstitial space expands by approximately 60 % at sleep onset in mice, accelerating β-amyloid peptide clearance roughly twice as fast as during wakefulness. Human kinetics have not been measured directly to date; the animal observation provides the mechanistic rationale for maximising time in deep sleep. (lien)
Muscular strength and dementia
Grip strength is a systemic proxy for cognitive risk. A UK Biobank cohort of 340,212 participants followed for 8.5 years documents a linear association: each +5 kg of grip strength corresponds to an approximately 12.6 % lower risk of incident Alzheimer's disease and an approximately 21.2 % lower risk of vascular dementia. (lien)
B vitamins and homocysteine
The VITACOG trial randomised 271 older subjects with mild cognitive impairment; in the 168 who completed the MRI arm, it documented a 30 % reduction in annual brain atrophy under B9-B12-B6 supplementation, and a 53 % reduction in subjects whose plasma homocysteine exceeded 13 µmol/L at baseline. Elevated homocysteine signals deficient methylation of the one-carbon cycle. (lien)
Mitochondria and PQQ
Four placebo-controlled trials document that PQQ supplementation for 12 weeks improves selective attention, verbal memory or language depending on the trial, in older adults as well as in adults aged 20 to 40. Three trials at 20 mg per day, the fourth at 21.5 mg, on a few dozen participants each. (lien)
Aerobic exercise and the hippocampus
A randomised trial on 120 older adults aged 55 to 80 documents that one year of moderate aerobic exercise (3 sessions of 40 minutes per week) increases the volume of the anterior hippocampus by approximately 2 %, with improvements in spatial memory, equivalent to 1 to 2 years of rejuvenation of hippocampal volume. (lien)
What gets measured and how often
Four accessible markers frame cognitive monitoring at rest, outside acute episodes and outside infection. A closely spaced measurement may precede the expected kinetics and remain difficult to interpret; cadence is tailored to the marker and its repeatability.
Plasma homocysteine
Kinetics 6 to 12 weeks
Healthspan target: below 10 µmol/L
Fasting blood draw, outside acute episodes. A value above 13 µmol/L points to individualised B9-B12-B6 supplementation.
Grip strength
Kinetics weeks to months under structured training
Maintain above the age- and sex-stratified reference median
Clinic dynamometer or certified home-use sensor. Monthly tracking is relevant during the optimisation phase, quarterly thereafter.
hs-CRP
Kinetics range from days to weeks; variability depends on the method and context
Singular optimal zone at 1 mg/L or below, outside infectious episodes
The trajectory is interpreted from repeated measurements taken outside acute episodes and under comparable conditions. The same laboratory and method are preferable. Timing depends on the marker's kinetics and the applicable measurement uncertainty.
Validated cognitive scores (MoCA, ADAS-Cog)
Pragmatic follow-up horizon: 6 to 24 months
Stable or ascending trajectory on delayed recall, fluency and attention tests
A BioFINDER cohort of 743 subjects in preclinical or prodromal stages studied these scores over 12 to 96 months. To document a trajectory comparable with the study outcome, more than 6 months, and often 12 to 24 months, provides more informative follow-up. A measurement at 3 months may have limited scope; it is neither noise nor universally devoid of information. (lien)
The longitudinal backdrop
Three longitudinal signals complement the reading of the markers above.
- →Chronically elevated cortisol inscribes its cost in the hippocampal structure: a cohort of older adults followed for 5 years with cerebral imaging documented that durably elevated salivary basal cortisol predicts reductions in hippocampal volume and hippocampus-dependent memory deficits. (lien)
- →The DunedinPACE epigenetic clock is associated with cognitive decline and incident dementia in a longitudinal cohort. This observation defines neither a universal individual response kinetics nor a change threshold; follow-up uses the same test and accounts for its repeatability. (lien)
- →The Lancet Commission 2024 estimated that 14 modifiable factors account for approximately 45 % of dementia risk in the global population: hearing, vision, smoking, hypertension, obesity, physical inactivity, diagnosed depression, social isolation, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, low education, and prolonged exposure to elevated LDL-C. (lien)
To integrate these markers into a feedback loop
Emerging frontier
Three pharmacological and physical axes fall outside the oral nutritional perimeter retained here, but converge on neuroplasticity and the BDNF-TrkB-mTOR synaptogenesis cascade. They fall strictly within the specialised medical pathway.
Intranasal esketamine (Spravato)
Approved by the FDA in 2019 for treatment-resistant major depressive disorder in adults receiving an oral antidepressant. Mechanism: NMDA antagonism triggering a BDNF-TrkB-mTOR synaptogenesis cascade, with measurable clinical effects within hours to 24 hours. Outside the oral nutritional perimeter retained here. (lien)
Psilocybin
A randomised controlled trial on 59 subjects with moderate to severe major depressive disorder documents that two psilocybin doses framed by 6 weeks of clinical accompaniment are equivalent to escitalopram (standard SSRI), with superiority on several secondary endpoints. Status: phase III clinical trials in progress. Outside the oral nutritional perimeter retained here. (lien)
Transcranial photobiomodulation
Near-infrared laser (810 nm) applied to the skull is documented at pilot scale on cognitive function in mild cognitive impairment and mild Alzheimer's disease. No phase III pivotal study to date. Exploratory status, outside the oral nutritional perimeter retained here.
